22157.jpg
Liquid Biopsy Market, 2027
September 17, 2020 05:58 ET | Research and Markets
Dublin, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The "Global Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional &...
22157.jpg
North America $3.5 Billion Liquid Biopsy Market to 2027: Consistent Launch of New Products
September 10, 2020 10:48 ET | Research and Markets
Dublin, Sept. 10, 2020 (GLOBE NEWSWIRE) -- The "North America Liquid Biopsy Market to 2027 - Regional Analysis and Forecasts by Product & Services; Sample; Application; End User; and, Country"...
22157.jpg
Europe Liquid Biopsy Market to 2027 - Regional Analysis and Forecasts by Product & Services, Sample, Application, & End User
September 08, 2020 06:33 ET | Research and Markets
Dublin, Sept. 08, 2020 (GLOBE NEWSWIRE) -- The "Europe Liquid Biopsy Market to 2027 - Regional Analysis and Forecasts by Product & Services; Sample; Application; End User; and, Country" report...
Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs
March 21, 2018 07:41 ET | Exosome Diagnostics
Waltham, MA, March 21, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., is thrilled to announce the appointment of Dr. Grannum Sant as Head of Medical Affairs.  As an internationally recognized...
Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor
March 14, 2018 07:30 ET | Exosome Diagnostics
Boston, MA, March 14, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., a market leader in liquid biopsy and the world’s first exosome-based diagnostics company announces a collaboration...
Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed
February 01, 2018 07:35 ET | Exosome Diagnostics
Waltham, MA, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network
December 04, 2017 07:33 ET | Exosome Diagnostics
Boston, MA, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that it has executed an agreement for coverage of its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics to Present a Novel Atlas of Exosomal mRNA and Long non-coding RNA Across Biofluids at American Society of Exosomes and Microvesicles Annual Meeting
October 11, 2017 07:30 ET | Exosome Diagnostics
Waltham, MA, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. will be presenting the company’s cutting edge long-RNAseq platform at this year’s American Society of Exosomes and...
Exosome Diagnostics Launches the MedOncAlyzer™ Pan-Cancer Panel
August 09, 2017 09:02 ET | Exosome Diagnostics
Waltham, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, a leader in the liquid biopsy market, today announced the launch of the MedOncAlyzer 170, the first liquid biopsy pan-cancer...
Exosome Diagnostics Presents Breakthrough Liquid Biopsy Technologies at BIO International Convention
June 22, 2017 11:54 ET | Exosome Diagnostics
Boston, MA, June 22, 2017 (GLOBE NEWSWIRE) -- John Boyce, President and CEO of Exosome Diagnostics Inc., a leader in the liquid biopsy space, presented a talk entitled “The True Liquid Biopsy”...